News & Events

Redbiotec opened its new office and laboratory in Schlieren, near Zurich, alongside an established core of several successful bioech companies.

Redbiotec has received financial support through the Volkswirtschaftsstiftung.

Redbiotec has negotiated an exclusive license deal with the ETH Zürich over patented MultiBac technology and the ETH has now become a partner and shareholde of Redbiotec.

Redbiotec was incoporated as an Aktiengesellschaft. All founders of the patented MultiBac technology are shareholders of Redbiotec AG. Soon the ETH Zürich will become shareholder too.

Under the former name XpresSys the team of Redbiotec wins the second prize of the Venture 2006. This success is based on the excellent businessplan, the attractive technology and on the strong founder team. Redbiotec was superior on nearly 100 other projects.Venture 2006 is an initiative of the ETH Zurich and McKinsey & Company, Switzerland. The Swiss-wide business plan competition supports young entrepreneurs in founding a company. Venture 2006 – as did Venture 98, 2000, 2002 and 2004 – aims to put to use untapped innovation potential by encouraging young entrepreneurs to develop a business idea. A number of renowned companies from Swiss industry and commerce sponsor the competition.